Hao Yi-Xuan, Li Chen-Rui, Lu Zhi-Jie, Kong Nan, Huang Rong-Hua, Ma Shu-Yan, Zhou Wen-Fei, Jiao Hao, Qiu Yue, Yu Yuan-Feng, Lv Bing-Wei, Tang Hai-Liang, Chen Jian, Wei Nai-Li
Department of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, NO.57 Changping Road, Jinping District, Shantou, 515041, Guangdong, China.
Department of Anesthesiology, Shijiazhuang Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
J Transl Med. 2025 Jul 10;23(1):767. doi: 10.1186/s12967-025-06736-4.
Ischemic stroke induces irreversible cerebral tissue damage, a condition exacerbated by the brain's limited endogenous neuroplasticity and inability to regenerate neurons. While neural circuit reorganization holds therapeutic potential, its efficacy is hindered by pathological barriers such as glial scarring, chronic inflammation, and neurotrophic factor deficiency. Although pharmacological and interventional methods for stroke have been well developed, their functional recovery outcomes remain suboptimal. Emerging neural regeneration paradigms, particularly stem cell-based strategies (encompassing neural stem cell transplantation, neural progenitors grafts, and 3D brain organoid implantation), offer novel solutions to these challenges. However, critical limitations persist in conventional stem cell approaches: (1) compromised synaptic integration efficacy hinders functional neural circuit reconstruction; (2) the absence of functional vascular niches coupled with deficient astrocyte-mediated support and extracellular matrix signaling; (3) restricted regenerative capacity despite theoretical multipotent differentiation potential. Recent breakthroughs in cerebral organoid technology have revolutionized neurological disease modeling and neural repair research. Building upon this paradigm shift, our study mechanistically interrogates neuroplastic remodeling processes following ischemic stroke, while critically evaluating the therapeutic efficacy and inherent limitations of stem cell-based interventions. This affirms the critical role of 3D human cerebral organoid transplantation in the reconstruction of neural circuits. Additionally, we further summarize the utility of organoid-based disease models and address associated ethical and societal concerns. Future efforts should prioritize the clinical translation of organoid transplantation for ischemic stroke, aiming to mitigate neurological deficits and restore functional recovery.
缺血性中风会导致不可逆的脑组织损伤,而大脑有限的内源性神经可塑性和神经元再生能力的缺失会使这种情况恶化。虽然神经回路重组具有治疗潜力,但其疗效受到诸如胶质瘢痕形成、慢性炎症和神经营养因子缺乏等病理障碍的阻碍。尽管中风的药理学和介入治疗方法已经得到了很好的发展,但其功能恢复结果仍然不尽人意。新兴的神经再生模式,特别是基于干细胞的策略(包括神经干细胞移植、神经祖细胞移植和三维脑类器官植入),为这些挑战提供了新的解决方案。然而,传统干细胞方法仍然存在关键局限性:(1)突触整合效率受损阻碍了功能性神经回路的重建;(2)缺乏功能性血管微环境,同时星形胶质细胞介导的支持和细胞外基质信号不足;(3)尽管理论上具有多能分化潜力,但再生能力有限。脑类器官技术的最新突破彻底改变了神经疾病建模和神经修复研究。基于这一范式转变,我们的研究从机制上探究了缺血性中风后的神经可塑性重塑过程,同时严格评估了基于干细胞的干预措施的治疗效果和内在局限性。这证实了三维人类脑类器官移植在神经回路重建中的关键作用。此外,我们进一步总结了基于类器官的疾病模型的实用性,并解决了相关的伦理和社会问题。未来的努力应优先考虑将类器官移植用于缺血性中风的临床转化,旨在减轻神经功能缺损并恢复功能恢复。